×
GSK Basic EPS 2010-2025 | GSK
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
GSK basic eps for the twelve months ending March 31, 2025 was
$1.96
, a
29.43% decline
year-over-year.
GSK annual basic eps for 2024 was
$0.002B
, a
46.61% decline
from 2023.
GSK annual basic eps for 2023 was
$0.003B
, a
67.08% decline
from 2022.
GSK annual basic eps for 2022 was
$0.009B
, a
205.15% increase
from 2021.
View More
GSK Basic EPS 2010-2025 | GSK
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
GSK annual basic eps for 2024 was
$0.002B
, a
46.61% decline
from 2023.
GSK annual basic eps for 2023 was
$0.003B
, a
67.08% decline
from 2022.
GSK annual basic eps for 2022 was
$0.009B
, a
205.15% increase
from 2021.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$209.6B
Amgen (AMGN)
$149.1B
Gilead Sciences (GILD)
$130.2B
Vertex Pharmaceuticals (VRTX)
$125.6B
Bristol Myers Squibb (BMY)
$100.2B
CSL (CSLLY)
$74.3B
Regeneron Pharmaceuticals (REGN)
$61.6B
Argenex SE (ARGX)
$36.2B
Alnylam Pharmaceuticals (ALNY)
$30.5B
BioNTech SE (BNTX)
$23.7B
BeiGene (ONC)
$22.8B
Biogen (BIIB)
$17.4B
Genmab (GMAB)
$13.3B
Genmab (GNMSF)
$13.3B
Insmed (INSM)
$13.2B
BioMarin Pharmaceutical (BMRN)
$11.3B
Illumina (ILMN)
$11.3B
Incyte (INCY)
$11.3B
Ascendis Pharma (ASND)
$10.1B
Exelixis (EXEL)
$10B
Swedish Orphan Biovitrum (BIOVF)
$9.6B
Moderna (MRNA)
$9.6B
QIAGEN (QGEN)
$9B
Exact Sciences (EXAS)
$7.7B
Bio-Techne Corp (TECH)
$7.6B
Repligen (RGEN)
$7.3B
Halozyme Therapeutics (HALO)
$7.3B
Roivant Sciences (ROIV)
$7.2B
Revolution Medicines (RVMD)
$6.8B
Bio-Rad Laboratories (BIO.B)
$6.3B